BioCentury | Aug 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jul 10, 2018
Distillery Therapeutics


INDICATION: Breast cancer Cell culture studies suggest promoting interactions between miR-34a and tRNA-iMet could help treat breast cancer. In a panel of human breast cancer cell lines, levels of miR-34a were lower and levels of...
BioCentury | Nov 6, 2017
Distillery Therapeutics


INDICATION: Bronchopulmonary dysplasia (BPD); acute lung injury Patient sample, mouse and cell culture studies suggest inhibiting miR-34a could help treat BPD and acute lung injury (ALI) in neonates. In postmortem lung tissue samples from premature...
BioCentury | Sep 21, 2017
Translation in Brief

No vehicle, no problem

A Purdue University team has developed a ligand-targeted method to deliver microRNA (miRNA) mimics to tumors without relying on vehicles or compromising miRNA processing. The researchers think their folate receptor -targeted miRNAs, or “FolamiRs,” could...
BioCentury | Sep 19, 2017
Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains A folate receptor-targeted system could help deliver therapeutic miRNA mimics to folate receptor-expressing cancers. The delivery system involves generating an miRNA passenger strand containing 2'-O-methyl-modified bases to enhance stability, conjugating its 5'...
BioCentury | Jul 10, 2017
Distillery Therapeutics

Autoimmune disease

INDICATION: Rheumatoid arthritis (RA) Patient sample and mouse studies suggest inhibiting miR-34a could help treat RA. In dendritic cells (DCs) in synovial tissue samples from patients, levels of miR-34a were higher than in DCs in...
BioCentury | May 16, 2017
Financial News

Synlogic finds public route, raises $42M

Synthetic biology company Synlogic Inc. (Cambridge, Mass.) will become a publicly traded entity via a reverse merger with Mirna Therapeutics Inc. (NASDAQ:MIRN). The combined company will keep Synlogic's name and develop that company's programs, including...
BioCentury | Sep 26, 2016
Clinical News

MRX34: Phase I discontinued

Mirna voluntarily terminated an open-label, dose-escalation, dose-expansion, U.S. and Korean Phase I trial of IV MRX34 after a fifth, immune-related serious adverse event was reported in patients who received the compound. The company said the...
BioCentury | Oct 2, 2015
Financial News

Edge, Mirna price IPOs

Edge Therapeutics Inc. (NASDAQ:EDGE) and Mirna Therapeutics Inc. (NASDAQ:MIRN) each began trading Thursday after pricing IPOs. Edge gained $1.94 (18%) to $12.94 after it raised $80.5 million through the sale of 7.3 million shares at...
BioCentury | Aug 26, 2015
Financial News

IPO roundup: Mirna, RainDance

Cancer company Mirna Therapeutics Inc. (Austin, Texas) filed to go public, while genetic research tool play RainDance Technologies Inc. (Billerica, Mass.) pulled its IPO. Mirna proposed to raise up to $80.5 million in an IPO...
Items per page:
1 - 10 of 39